PMID- 32356612
OWN - NLM
STAT- MEDLINE
DCOM- 20210902
LR  - 20210902
IS  - 1365-2230 (Electronic)
IS  - 0307-6938 (Linking)
VI  - 45
IP  - 7
DP  - 2020 Oct
TI  - The risk of interstitial lung disease during biological treatment in Japanese 
      patients with psoriasis.
PG  - 853-858
LID - 10.1111/ced.14259 [doi]
AB  - BACKGROUND: With the increasing use of biological agents for the treatment of 
      psoriasis, the numbers of patients with interstitial lung disease (ILD) 
      associated with biologics have also increased. Many of these cases were 
      associated with tumour necrosis factor (TNF)-alpha inhibitors, but cases associated 
      with other families of biologics have also been reported in Japan. AIM: To 
      analyse the background factors of patients who developed ILD, and to discuss 
      better management of biological treatment. METHOD: We reviewed 246 patients with 
      psoriasis who were treated with biological agents in our department to identify 
      any pulmonary adverse events (AEs). Data on patients who developed ILD were 
      extracted to analyse background factors, clinical type of psoriasis, time to 
      onset of ILD, pre-existing ILD, smoking habit and prescribed drugs. RESULTS: 
      Pulmonary AEs were seen in 22 cases, of which 11 were diagnosed as drug-induced 
      ILD. The causative drugs were mainly TNF-alpha inhibitors, accounting for eight cases 
      (six treated with infliximab, two with adalimumab). The remaining three cases 
      were associated with secukinumab, ustekinumab and ixekizumab (n = 1 each). 
      Notably, these three cases also had a history of drug-induced ILD. CONCLUSION: 
      Patients with a history of drug-induced ILD seem to be more susceptible to 
      developing another ILD induced by biologics, even if treated with interleukin-17 
      inhibitors. Thorough screening of risk factors and evaluation for eligibility, 
      and careful monitoring during treatment are the best solutions to avoid serious 
      pulmonary AE. Early detection and precise diagnosis of pulmonary AEs, especially 
      differentiation from infectious diseases, is essential for managing biological 
      treatment.
CI  - (c) 2020 British Association of Dermatologists.
FAU - Matsumoto, Y
AU  - Matsumoto Y
AUID- ORCID: 0000-0001-7429-5487
AD  - Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
FAU - Abe, N
AU  - Abe N
AD  - Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
FAU - Tobita, R
AU  - Tobita R
AD  - Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
FAU - Kawakami, H
AU  - Kawakami H
AD  - Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
FAU - Nakayama, H
AU  - Nakayama H
AD  - Department of Respiratory Medicine, Tokyo Medical University, Tokyo, Japan.
FAU - Setoguchi, Y
AU  - Setoguchi Y
AD  - Department of Pulmonology, Graduate School of Medical and Dental Sciences, Tokyo 
      Medical and Dental University, Tokyo, Japan.
FAU - Tsuboi, R
AU  - Tsuboi R
AD  - Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
FAU - Okubo, Y
AU  - Okubo Y
AUID- ORCID: 0000-0002-9526-1259
AD  - Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200629
PL  - England
TA  - Clin Exp Dermatol
JT  - Clinical and experimental dermatology
JID - 7606847
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biological Factors)
RN  - 0 (MUC1 protein, human)
RN  - 0 (Mucin-1)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - B72HH48FLU (Infliximab)
RN  - BTY153760O (ixekizumab)
RN  - DLG4EML025 (secukinumab)
RN  - FU77B4U5Z0 (Ustekinumab)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab/adverse effects
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/adverse effects
MH  - Antirheumatic Agents/adverse effects
MH  - Biological Factors/*adverse effects/therapeutic use
MH  - Early Diagnosis
MH  - Female
MH  - Humans
MH  - Infliximab/adverse effects
MH  - Japan/epidemiology
MH  - Lung Diseases, Interstitial/*chemically induced/epidemiology/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Mucin-1/blood
MH  - Psoriasis/complications/*drug therapy/pathology
MH  - Risk Factors
MH  - Tumor Necrosis Factor Inhibitors/*adverse effects
MH  - Ustekinumab/adverse effects
EDAT- 2020/05/02 06:00
MHDA- 2021/09/03 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/02/12 00:00 [received]
PHST- 2020/04/18 00:00 [revised]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2021/09/03 06:00 [medline]
PHST- 2020/05/02 06:00 [entrez]
AID - 10.1111/ced.14259 [doi]
PST - ppublish
SO  - Clin Exp Dermatol. 2020 Oct;45(7):853-858. doi: 10.1111/ced.14259. Epub 2020 Jun 
      29.